Last Updated on February 25, 2025 by The Health Master
USFDA inspection
Zydus Lifesciences has announced that a US Food and Drug Administration inspection (USFDA inspection) at its Active Pharmaceutical Ingredient (API) facility in Ambernath, Maharashtra, has been concluded successfully.
The outcome of the inspection, conducted from February 10th to 14th, 2025, is a success, with zero observations issued.
Regulatory Compliance
The successful completion of the USFDA inspection with no observation is a testament to the company’s good quality management systems and its manufacturing of safe and efficacious APIs.
The inspection, conducted by a team of experts from USFDA experts, scrutinized various aspects of the manufacturing process, including:
Adherence to international Good Manufacturing Practices (GMP) guidelines is paramount for pharmaceutical manufacturers.
Quality control procedures and measures are implemented throughout the manufacturing process to ensure the consistency and safety of the manufactured drugs.
Maintaining accurate and reliable data records is important for regulatory compliance and patient safety with respect to the data integrity.
Zero Observations:
It is a remarkable achievement for the company that these found zero observations during the USFDA inspection.
What is the significance of the USFDA inspection?
The USFDA inspection is a critical evaluation of a pharmaceutical manufacturing facility’s adherence to regulatory quality and safety standards.
What does “zero observations” mean?
“Zero observations” indicates that the USFDA inspectors did not find any deviations from regulatory standards requirements during their inspection.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
USFDA inspection concluded at Alembic Pharma with no observation
USFDA issues positive EIR to Alembic for Panelav facility
USFDA issued Form 483 with observation to Torrent Pharma, Pithampur plant
USFDA Inspection successfully completed at Indian firm Laurus Labs
USFDA inspection finds these lapses at Zydus Lifesciences
USFDA inspection with positive VAI to Dr. Reddy’s Lab for its API facility
Opportunity to Supply APIs to Venezuela: Pharmexcil
Digital program for Pharmacists launched
NPPA revised ceiling price of 2 formulations: February 2025
Extension of the deadline for Revised Schedule M: Final notification
NPPA fixed retail price of 42 formulations: February 2025
Drug prices display is mandatory for all pharmacies: NPPA
New export norms for Erythromycin Stearate Tablets: DGFT
CDSCO Approval: For Vedolizumab Biosimilar Clinical Trial
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
